AGER and pulmonary fibrosis: Indeed, increased amounts of RAGE and/or RAGE ligands have been reported in pulmonary fibrosis, acute lung injury (ALI), ARDS, pneumonia, and cystic fibrosis (CF), and were demonstrated to sustain the pathological outcomes in these conditions [71].